Facebook
X
LinkedIn
Forward
Contemporary Multi-Disciplinary Management of Bladder Cancer
The management of bladder cancer is evolving across the spectrum of disease and stage and this educational activity is extremely valuable to the ASTRO membership. This activity addresses the role of radiation therapy in the context of emerging systemic therapy paradigms, immunobiologics and a growing emphasis on organ preservation strategies. In addition, appropriate post-operative management and care for patients with oligometastatic disease needs to be addressed. The activity touches on molecular subtypes and functional/MRI imaging. Panel representation includes radiation oncology, medical oncology, urology, pathology and radiology experts.
Topics:
- Radiation Therapy in Contemporary Management of Localized and Advanced Bladder Cancer
Leslie K. Ballas, MD, FASTRO - Contemporary Management of Bladder Cancer: The Urologic Oncology Perspective
Jonathan L. Wright, MD, MS, FACS - Radiation Therapy in NMIBC and in Post-operative Management of Bladder Cancer
Brian C. Baumann, MD - Systemic Therapy in the Management of Localized and Advanced Bladder Cancer
Rosa Nadal, MD, PhD - Q and A
Omar Y. Mian, MD, PhD – Moderator
Full Panel
This activity is available from June 4, 2026, through 11:59 p.m. Eastern time on June 3, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the contemporary management of patients with muscle invasive bladder cancer in a multidisciplinary setting.
- Understand the role of molecular subtyping, MRI, emerging systemic therapy including immunobiologics in the management of localized and advanced bladder cancer.
- Describe the role of adjuvant radiation and systemic therapy in the management of post cystectomy patients.
Moderator:
- Omar Y. Mian, MD, PhD, is employed by University of Washington/Fred Hutchinson Cancer Center. Dr. Mian has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- Leslie K. Ballas, MD, FASTRO, is employed by Cedars-Sinai Medical Center. Dr. Ballas serves in uncompensated roles with Seagen/Astellas and Merck. Dr. Ballas receives honoraria from UpToDate and MdxHealth.
- Jonathan L. Wright, MD, MS, FACS, is employed by University of Washington. Dr. Wright has no relevant financial relationship with ineligible companies to disclose.
- Brian C. Baumann, MD, is employed by University of Pennsylvania/Springfield Clinic. Dr. Baumann receives compensation/payment from Boston Scientific.
- Rosa Nadal, MD, PhD, is employed by University of Washington Fred Hutchinson Cancer Center. Dr. Nadal has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until June 3, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.